-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, IuypjtTDMyOB+7FT9GlF+Rz3SlXOEMD/fq9t0WQ2ET9Rx3+SdHAshnLgRipkeX1a BzE9ChLS2dZgEfs6zt+YuQ== 0000898432-99-000150.txt : 19990212 0000898432-99-000150.hdr.sgml : 19990212 ACCESSION NUMBER: 0000898432-99-000150 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 19990211 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: MGI PHARMA INC CENTRAL INDEX KEY: 0000702131 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 411364647 STATE OF INCORPORATION: MN FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: SEC FILE NUMBER: 005-33822 FILM NUMBER: 99531243 BUSINESS ADDRESS: STREET 1: 9900 BREN RD EAST STE 300E STREET 2: C/O OPUS CENTER MINNETONKA MINNESOTA CITY: MINNEAPOLIS STATE: MN ZIP: 55343 BUSINESS PHONE: 6129357335 MAIL ADDRESS: STREET 1: OPUS CENTER STREET 2: 9900 BREN ROAD EAST SUITE 300E CITY: MINNEAPOLIS STATE: MN ZIP: 55343 FORMER COMPANY: FORMER CONFORMED NAME: MOLECULAR GENETICS INC DATE OF NAME CHANGE: 19900812 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: AVENIR CORP/DC CENTRAL INDEX KEY: 0001033475 STANDARD INDUSTRIAL CLASSIFICATION: UNKNOWN SIC - 0000 [0000] IRS NUMBER: 541146619 STATE OF INCORPORATION: VA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: 1725 K STREET N W STREET 2: SUITE 410 CITY: WASHINGTON STATE: DC ZIP: 20006 BUSINESS PHONE: 2026594427 SC 13G/A 1 ------------------------------ OMB APPROVAL ------------------------------ OMB Number Expires: Estimated average burden hours per response ....... 0.5 ------------------------------ SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)(1) MGI Pharma Inc. - -------------------------------------------------------------------------------- (Name of Issuer) Common Stock - -------------------------------------------------------------------------------- (Title of Class of Securities) 552880106 - -------------------------------------------------------------------------------- (CUSIP Number) - -------------------------------------------------------------------------------- (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [_] Rule 13d-(c) [_] Rule 13d-1(d) - ---------- (1) The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). (SC13G-07/98) CUSIP No. 552880106 13G Page 2 of 5 Pages ________________________________________________________________________________ 1. NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY) Avenir Corporation IRS ID No.: 54-1146619 ________________________________________________________________________________ 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [_] (b) [X] ________________________________________________________________________________ 3. SEC USE ONLY ________________________________________________________________________________ 4. CITIZENSHIP OR PLACE OF ORGANIZATION Commonwealth of Virginia ________________________________________________________________________________ NUMBER OF 5. SOLE VOTING POWER 844,206 SHARES _________________________________________________________________ BENEFICIALLY 6. SHARED VOTING POWER 0 OWNED BY _________________________________________________________________ EACH 7. SOLE DISPOSITIVE POWER 844,206 REPORTING _________________________________________________________________ PERSON 8. SHARED DISPOSITIVE POWER 0 WITH ________________________________________________________________________________ 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 844,206 ________________________________________________________________________________ 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* N/A [_] ________________________________________________________________________________ 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 6.1% ________________________________________________________________________________ 12. TYPE OF REPORTING PERSON* IA ________________________________________________________________________________ *SEE INSTRUCTIONS BEFORE FILLING OUT! CUSIP No. 552880106 13G Page 3 of 5 Pages ________________________________________________________________________________ Item 1(a). Name of Issuer: MGI Pharm Inc. ________________________________________________________________________________ Item 1(b). Address of Issuer's Principal Executive Offices: 9900 Bren Road East, Suite 300E c/o Opus Center Minnetonka Minnesota Minneapolis, MN 55343 ________________________________________________________________________________ Item 2(a). Name of Person Filing: Avenir Corporation ________________________________________________________________________________ Item 2(b). Address of Principal Business Office, or if None, Residence: 1725 K Street, NW Suite 410 Washington, DC 20006 ________________________________________________________________________________ Item 2(c). Citizenship: Commonwealth of Virginia ________________________________________________________________________________ Item 2(d). Title of Class of Securities: Common Stock ________________________________________________________________________________ Item 2(e). CUSIP Number: 552880106 ________________________________________________________________________________ Item 3. If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a: (a) [_] Broker or dealer registered under Section 15 of the Exchange Act. (b) [_] Bank as defined in Section 3(a)(6) of the Exchange Act. (c) [_] Insurance company as defined in Section 3(a)(19) of the Exchange Act. (d) [_] Investment company registered under Section 8 of the Investment Company Act. (e) [X] An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E); (f) [_] An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F); (g) [_] A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G); (h) [_] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act; (i) [_] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act; (j) [_] Group, in accordance with Rule 13d-1(b)(1)(ii)(J). If this statement is filed pursuant to Rule 13d-1(c), check this box. [_] CUSIP No. 552880106 13G Page 4 of 5 Pages Item 4. Ownership. Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. (a) Amount beneficially owned: 884,206 (b) Percent of class: 6.1% (c) Number of shares as to which such person has: (i) Sole power to vote or to direct the vote 884,206 (ii) Shared power to vote or to direct the vote 0 (iii) Sole power to dispose or to direct the disposition of 884,206 (iv) Shared power to dispose or to direct the disposition of 0 ________________________________________________________________________________ Item 5. Ownership of Five Percent or Less of a Class. Not applicable. If this statment is being giled to report the fat taht as f the date hereof the reporting person has ceased to be the bencial owner of more than 5 percent of the class of securities, check the following /X/ ________________________________________________________________________________ Item 6. Ownership of More Than Five Percent on Behalf of Another Person. Not applicable. ________________________________________________________________________________ Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company. Not applicable. ________________________________________________________________________________ Item 8. Identification and Classification of Members of the Group. Not applicable. ________________________________________________________________________________ Item 9. Notice of Dissolution of Group. Not applicable. ________________________________________________________________________________ Item 10. Certifications. (a) The following certification shall be included if the statement is filed pursuant to Rule 13d-1(b): "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect." (b) The following certification shall be included if the statement is filed pursuant to Rule 13d-1(c): "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect." SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. February 9, 1999 ---------------------------------------- (Date) /s/ Charles G. Mackall, Jr. ---------------------------------------- (Signature) Charles G. Mackall, Jr., President ---------------------------------------- (Name/Title) Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7(b) for other parties for whom copies are to be sent. Attention. Intentional misstatements or omissions of fact constitute federal criminal violations (see 18 U.S.C. 1001). -----END PRIVACY-ENHANCED MESSAGE-----